Basigin rs8259 Polymorphism Confers Decreased Risk of Chronic Heart Failure in a Chinese Population

Mu-Peng Li, Xiao-Lei Hu, Yong-Long Yang, Yan-Jiao Zhang, Ji-Peng Zhou, Li-Ming Peng, Jie Tang and Xiao-Ping Chen
Additional contact information
Mu-Peng Li: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Xiao-Lei Hu: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Yong-Long Yang: Haikou People’s Hospital and Affiliated Haikou Hospital of Xiangya Medical School, Central South University, Haikou 570311, China
Yan-Jiao Zhang: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Ji-Peng Zhou: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Li-Ming Peng: Department of Cardiovascular Medicine, Xiangya Hospital, Central South University, Changsha 410008, China
Jie Tang: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
Xiao-Ping Chen: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China

IJERPH, 2017, vol. 14, issue 2, 1-11

Abstract: Left ventricular remodeling is an essential risk factor contributing to the pathogenesis of chronic heart failure (CHF). Basigin (BSG) promotes cardiovascular inflammation and myocardial remodeling processes by induction of extracellular matrix metalloproteinases and inflammatory cytokines. BSG rs8259 polymorphism was associated with BSG expression and risk of acute coronary syndrome. Therefore, we investigated whether rs8259 polymorphism contributes to risk and prognosis of CHF in Chinese patients. In total 922 adult patients with CHF and 1107 matched healthy controls were enrolled. BSG rs8259 polymorphism was genotyped using PCR-restriction fragment length polymorphism. Whole blood BSG mRNA expression data from Genotype-Tissue Expression project was accessed. Evaluation of follow-up data was performed in only 15.2% (140) of the patients with CHF. BSG rs8259 TT genotype was associated with a decreased risk of CHF (OR = 0.83, 95% CI = 0.72–0.96, p = 0.010), especially in patients with hypertension (OR = 0.80, 95% CI = 0.68–0.95, p = 0.011) and coronary heart disease (OR = 0.81, 95% CI = 0.69–0.96, p = 0.013) after adjustment for multiple cardiovascular risk factors. Rs8259 T allele was associated with decreased BSG mRNA in whole blood from 338 healthy normal donors ( p = 1.31 × 10 ?6 ). However, rs8259 polymorphism failed to exhibit an association with cardiovascular mortality ( p = 0.283). BSG rs8259 polymorphism may contribute to decreased risk of CHF in a Chinese Han population.

Keywords: Basigin; polymorphism; chronic heart failure; prognosis (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/14/2/211/pdf (application/pdf)
https://www.mdpi.com/1660-4601/14/2/211/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:14:y:2017:i:2:p:211-:d:91040

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().